Hanways Chempharm Co., Limited, the former is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China.  We specialize in sourcing and supplying APIs, pharmaceutical intermediates, and fine chemicals for worldwide markets.
The founder has decades experience in pharmaceutical industry. We are not just a trading company, but a comprehensive solutions supplier.  With our sound knowledge of pharmaceutical business, to integrate resource and adapt to all different demands of markets is our advantage. We are a small but dynamic and energetic company with high efficient and high flexible decision making system. 
Our products cover oncology APIs and intermediates, antiviral APIs and intermediates, cardiovascular APIs and intermediates, hormones APIs and intermediates and so on. Cater to the developing of pharmaceutical industry, we focus on the niche and new compounds.
Our business philosophy is customer-oriented, reliability and trustworthy, better service and win-win. We will take every effort to supply quality products to seek mutual development and benefits.
 

Brief Description

Medical use

Clomifene is useful in those who are infertile due to anovulation or oligoovulation. Evidence is lacking for the use of clomifene in those who are infertile without a known reason. In such cases, studies have observed a clinical pregnancy rate 5.6% per cycle with clomifene treatment vs. 1.3%–4.2% per cycle without treatment.

Clomifene has also been used with other assisted reproductive technology to increase success rates of these other modalities.

Proper timing of the drug is important; it should be taken starting on about the fifth day of the cycle, and there should be frequent intercourse.

The following procedures may be used to monitor induced cycles:

Follicular monitoring with vaginal ultrasound, starting 4–6 days after last pill. Serial transvaginal ultrasound can reveal the size and number of developing follicles. It can also provide presumptive evidence of ovulation such as sudden collapse of the preovulatory follicle, and an increase in fluid volume in the rectouterine pouch. After ovulation, it may reveal signs of luteinization such as loss of clearly defined follicular margins and appearance of internal echoes.

Serum estradiol levels, starting 4–6 days after last pill

Post-coital test 1–3 days before ovulation to check whether there are at least 5 progressive sperm per HPF

Adequacy of LH surge by urine LH surge tests 3 to 4 days after last clomifene pill

Mid-luteal progesterone, with at least 10 ng/ml 7–9 days after ovulation being regarded as adequate.

Repeat dosing: This 5-day treatment course can be repeated every 30 days. The dosage may be increased by 50-mg increments in subsequent cycles until ovulation is achieved. It is not recommended by the manufacturer to use clomifene for more than 6 cycles.

It is no longer recommended to perform an ultrasound examination to exclude any significant residual ovarian enlargement before each new treatment cycle.

Clomifene is sometimes used in the treatment of male hypogonadism as an alternative to testosterone replacement therapy. It has been found to increase testosterone levels by 2- to 2.5-fold in hypogonadal men.

Clomifene has been used in the treatment of gynecomastia. It has been found to be useful in the treatment of some cases of gynecomastia but it is not as effective as tamoxifen or raloxifene for this indication. It has shown variable results for gynecomastia and hence is not recommended for treatment of the condition.

Our Factory: